Lumosity’s $2M Fine & the Risk of “Fake It ‘Til You Make It”

Generic placeholder image
Carl Niedbala

COO & Co-Founder

How Lumosity got in trouble

Lumosity, the San Francisco-based company offering brain-training tools, came under fire from the FTC this week for the deceptive advertising allegations.  Director of the FTC’s Bureau of Consumer Protection Jessica Rich said the following: “Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease. But Lumosity simply did not have the science to back up its ads.”

As a result of the FTC action, Lumosity has agreed to pay a $2M settlement as well as notify all of its users about the FTC action and offer a clear cancellation process before user accounts auto-renew.

Since inception in 2007, Lumosity raised $67.5M over the course of 4 rounds.  It currently has a user base topping 70 million globally and 2013 revenues (the most recent numbers available) of roughly $24M.

Lumosity always touted some research to back its claims, but apparently this was more of a case of the “fake it ’til you make it” mentality we’re all accustomed to in the startup marketing world.  Teams appear larger, products appear more robust, etc.  This mantra is both effective and necessary for most startups and allowed Lumosity to quickly amass a huge user base.   However, this is a good reminder of the risks that can come along with a bit of extra marketing embellishment.

How insurance can help

The good news is that with the proper insurance in place, Lumosity could be spared from a hefty bill here.  Beyond the settlement itself, the company will have to deal with the legal expenses and costs related to notifying its users.

There are a couple different insurance products that could kick in here to cover the company’s expenses.  In order to figure out which ones, we have to look at two things: the allegations and the type of claim.

The allegation here is deceptive advertising, general liability (GL) insurance could kick in to provide cover.  The “personal injury” protection provided by a general liability policy provides cover for libel, slander, misrepresentation, and more when present in the insured company’s advertising materials.

As for the type of claim, it’s important to note that this claim came in directly from the FTC.  Government entities have a tendency to personally name the directors and officers of the company in the action, and therefore put the execs’ personal assets at risk.  A directors and officers insurance policy could kick in here to add an extra layer of protection should this be the case.

Marketers at startups are aggressive (and they should be!), but it doesn’t mean that you should fly by the seat of your pants as a company.  Insurance is a simple tool to help mitigate the risks of a bullish marketing strategy.   Talk to us to learn more!

[vc_btn title=”GET A QUOTE” style=”outline-custom” outline_custom_color=”#ee2524″ outline_custom_hover_background=”#ee2524″ outline_custom_hover_text=”#ffffff” shape=”square” size=”lg” align=”center” link=”|||”]



Related Articles

January 26 • Directors & Officers

7 Crucial Cost & Drivers of D&O Insurance

Now more than ever, companies must safeguard their directors and officers — but how? Here’s an inside look at what drives D&O insurance prices.

November 10 • Directors & Officers

Insurance for Special Purpose Acquisition Companies

Special purpose acquisition companies (SPACs) are growing in popularity — but they also face new exposures. Here’s how to manage SPAC risks.

October 21 • Directors & OfficersRepresentations and Warranties Insurance

Insurance Policies You Need During Mergers & Acquisitions

M&As present high-growth companies plenty of opportunities for profit — and risk. Here are some insurance considerations for successful mergers and acquisitions.

October 7 • Directors & Officers

3 Key Takeaways from the Recent Frenzy of Tech IPOs

Several tech companies have gone public simultaneously. After reviewing each, here are some lessons we can learn from the IPO rush.

June 1 • Directors & OfficersNews

D&O Pricing Trends: Q2 Update

Amid the pandemic, D&O insurance has taken some unique turns. Here’s a look at our Q2 update for small businesses and mid-market companies alike.

life science VC
May 12 • Directors & Officers

VC Funding for Life Sciences Companies

VC funding for life sciences companies has evolved significantly in the past two decades. Here’s what you need to know about financing in the space.